Mablink Bioscience, a pre-clinical company pioneering the development of next-generation antibody-drug conjugates via its PSARLinkTM proprietary platform, announced an agreement to be acquired by Eli Lilly and Company. The biotechnology company is developing the next
Tags :Martin Aebi
The team included partner Harold Frey and counsel Martin Aebi (both Dispute Resolution).
The team was led by partner Harold Frey (pictured), counsel Martin Aebi and Fadri Lenggenhager as well as associate Severin Christen.
Lenz & Staehelin defended a Swiss bank against monetary claims raised by a banking software and outsourcing provider amounting to CHF 90 million plus interest.
